cyclophosphamide + docetaxel + pegylated liposomal doxorubicin

This is a combination chemotherapy regimen consisting of three agents: - Cyclophosphamide, an alkylating agent that crosslinks DNA and inhibits cell division. - Docetaxel, a taxane-class antineoplastic that stabilizes microtubules and prevents their depolymerization, thereby inhibiting mitosis. - Pegylated liposomal doxorubicin, an anthracycline antibiotic formulated in PEG-coated liposomes to improve pharmacokinetics and reduce cardiotoxicity compared to conventional doxorubicin. Doxorubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. This combination is used primarily as first-line or adjuvant therapy for breast cancer (including metastatic or node-positive early breast cancer). The regimen has demonstrated high response rates but is associated with significant hematologic toxicity (notably neutropenia) and potential cardiac toxicity. The substitution of pegylated liposomal doxorubicin for conventional doxorubicin may further reduce cardiotoxic risk while maintaining efficacy[1][5][7].

Brand names

TaxotereCaelyxDoxilCytoxan

Other names

cyclophosphamide + docetaxel + pegylated liposomal doxorubicinTAC (when using conventional doxorubicin), but not standard for the pegylated liposomal formulation